CytomX Therapeutics (NASDAQ:CTMX) Posts Quarterly Earnings Results, Misses Expectations By $0.14 EPS

CytomX Therapeutics (NASDAQ:CTMX) released its earnings results on Monday. The biotechnology company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14), FiscalAI reports. The business had revenue of $0.66 million for the quarter, compared to the consensus estimate of $7.33 million. CytomX Therapeutics had a return on equity of 44.49% and a net margin of 24.66%.

CytomX Therapeutics Trading Down 3.9%

Shares of CytomX Therapeutics stock opened at $4.68 on Monday. The firm has a market capitalization of $792.93 million, a PE ratio of 11.70 and a beta of 2.44. CytomX Therapeutics has a 12 month low of $0.40 and a 12 month high of $6.35. The business’s 50-day moving average price is $5.19 and its 200-day moving average price is $4.04.

Institutional Trading of CytomX Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Orbimed Advisors LLC purchased a new stake in CytomX Therapeutics during the second quarter valued at about $19,208,000. Commodore Capital LP purchased a new position in shares of CytomX Therapeutics in the second quarter worth about $17,462,000. Perceptive Advisors LLC bought a new stake in shares of CytomX Therapeutics in the 2nd quarter valued at about $15,876,000. State Street Corp lifted its stake in shares of CytomX Therapeutics by 697.1% in the 4th quarter. State Street Corp now owns 5,140,931 shares of the biotechnology company’s stock valued at $21,900,000 after acquiring an additional 4,495,949 shares during the last quarter. Finally, ADAR1 Capital Management LLC boosted its holdings in CytomX Therapeutics by 31.3% during the 3rd quarter. ADAR1 Capital Management LLC now owns 4,045,414 shares of the biotechnology company’s stock valued at $12,905,000 after acquiring an additional 964,000 shares during the period. 67.77% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

CTMX has been the subject of several research reports. Piper Sandler increased their price target on shares of CytomX Therapeutics from $6.50 to $10.00 and gave the company an “overweight” rating in a research report on Tuesday, January 20th. Guggenheim restated a “buy” rating and issued a $10.00 price objective on shares of CytomX Therapeutics in a research note on Monday, March 9th. Barclays increased their target price on CytomX Therapeutics from $8.00 to $10.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 4th. Finally, Cantor Fitzgerald increased their price target on shares of CytomX Therapeutics from $6.00 to $10.00 and gave the stock an “overweight” rating in a report on Wednesday, February 4th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.